CLPP-2068

CLPP-2068 is the orally active activator for human caseinolytic protease P (HsClpP) with an EC50 of 50.4 nM. CLPP-2068 exhibits anti-proliferative efficacy in OCI-LY10 cancer cell with an IC50 of 5.2 nM. CLPP-2068 decreases mitochondrial membrane potential, increases mitochondrial ROS levels, and induces mitochondrial dysfunction. CLPP-2068 arrests the cell cycle at G1 phase, and induces apoptosis in cell OCI-LY10. CLPP-2068 exhibits antitumor activity in mouse xenograft models[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; ClpP; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Field of Research

Cancer

Purity

97.41

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1NC(NCC2=CC=C(Br)C=C2)=NC3=C1CN([C@H](C)C3)CC4=CC(C#N)=CC=C4

Molecular Formula

C23H22BrN5O

Molecular Weight

464.36

References & Citations

[1]Sun M, et al., Harnessing the Magic Methyl Effect: Discovery of CLPP-2068 as a Novel HsClpP Activator for the Treatment of Diffuse Large B-Cell Lymphoma. J Med Chem. 2025 Feb 27;68 (4) :4287-4307.